Keywords: astrazeneca, licenses, preclinical-stage, tris, anglo-swedish, drug, major
AstraZeneca licenses preclinical-stage TRIs
Article | 16 February 2009
Anglo-Swedish drug major AstraZeneca has licensed a portfolio of preclinical triple reuptake inhibitor compounds for depression from USA-based research centers ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
